Clinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches

Movement Disorders

Volumn 29, Issue 11, 2014, Pages 1419-1428

  Sampaio, Cristina ^a   Borowsky, Beth ^a   Reilmann, Ralf ^b,c  

^a CHDI MANAGEMENT CHDI FOUNDATION   (United States)

^b Technology Park   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Clinical trials; Disease modification; Drug development; Endpoints; Huntington's disease; Phase I; Phase II; Phase III; Symptomatic treatment

Indexed keywords

BRAIN DEPTH STIMULATION; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; HUMAN; HUNTINGTON DISEASE; MEDLINE; OUTCOME ASSESSMENT; PROCEDURES; STATISTICS AND NUMERICAL DATA;

CLINICAL TRIALS AS TOPIC; DEEP BRAIN STIMULATION; DRUG DISCOVERY; HUMANS; HUNTINGTON DISEASE; OUTCOME ASSESSMENT (HEALTH CARE); PUBMED;

EID: 84907923806     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26021     Document Type: Review

References (60)

1. Walker FO. Huntington's disease. Lancet 2007;369:218-228.
2. Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012;27:31-41.
3. Ross CA, Aylward EH, Wild EJ, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 2014;10:204-216.
4. European Comission. Regulation EC N 1394/2007 of the European Parliament and of The Council of 13 Nivember 2007 on advanced therapies medicinal products. Sint-Gillis, Belgium: European Commission; 2007.
5. de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011;10:1049-1057.
6. The Huntington Study Group HI. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease. Mov Disord 2013;28:1407-1415.
7. Reilmann R. The pridopidine paradox in Huntington's disease. Mov Disord 2013;28:1321-1324.
8. Tabrizi SJ, Scahill RI, Durr A, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011;10:31-42.
9. Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
10. Bechtel N, Scahill RI, Rosas HD, et al. Tapping linked to function and structure in premanifest and symptomatic Huntington disease. Neurology 2010;75:2150-2160.
11. Tabrizi SJ, Scahill RI, Owen G, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 2013;12:637-649.
12. López-Sendón Moreno JL, García-Caldentey J, Regidor I, del Álamo M, García de Yébenes J. A 5-year follow-up of deep brain stimulation in Huntington's disease. Parkinsonism Relat Disord 2014;20:260-261.
13. Gonzalez V, Cif L, Biolsi B, et al. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study. J Neurosurg 2014;121:114-122.
14. U.S. Food and Drug Administration. Overview of device regulation. 2014. Available at: http://wwwfdagov/MedicalDevices/DeviceRegulationandGuidance/Overview/defaulthtm.
15. Vesper J. A prospective pilot trial for pallidal deep brain stimulation in Huntington's disease. 2014. http://chdifoundationorg/2014-conference/.
16. Rosenthal MH, David WT, John LC, Celia E, Jesse . Clinical development success rates for investigational drugs. Nat Biotechnol 2014;32:40-51.
17. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, Street SD. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today 2012;17:419-424.
18. Cummings JL, Morstorf T, Zhong K. Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther 2013;6:37.
19. ALZFORUM. PBT2. http://wwwalzforumorg/therapeutics/pbt2_br. Accessed 23 July 2014.
20. Shults C, Steardo L, Barone P, et al. Huntington's disease: effect of cysteamine, a somatostatin-depleting agent. Neurology 1986;36:1099-1102.
21. Gibrat C, Cicchetti F. Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:380-389.
22. Menalled LB, Kudwa AE, Oakeshott S, et al. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease. PloS One 2013;9:e99520.
23. Borrell-Pagès M, Canals JM, Cordelières FP, et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 2006;116:1410-1424.
24. Besouw M, Masereeuw R, van den Heuvel L, Levtchenko E. Cysteamine: an old drug with new potential. Drug Discov Today 2013;18:785-792.
25. Raptor Pharmaceuticals. Raptor Pharmaceuticals announces phase 2/3 clinical trial results with cysteamine (RP103) in Huntington's disease. 2014. Novato, CA: Raptor Pharmaceuticals.
26. Smith MR, Syed A, Lukacsovich T, et al. A potent and selective Sirtuin 1 inhibitor alleviates pathology in multiple animal and cell models of Huntington's disease. Hum Mol Genet 2014;23:2995-3007.
27. Süssmuth S, Landwehrmeyer G, Tabrizi S, et al. Q02 A randomised, double-blind, placebo-controlled phase IB pharmacodynamic study with selisistat (SEN0014196) in HD patients. J Neurol Neurosurg Psychiatry 2012;83(Suppl 1):A55.
28. Reilmann R, Squitieri F, Priller J, et al. Safety and tolerability of selisistat for the treatment of Huntington's disease: results from a randomized, double-blind, placebo-controlled phase II trial (S47.004). Neurology 2014;82(10 Suppl):S47.004.
29. Chappie T, Humphrey J, Menniti F, Schmidt C. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape. Curr Opin Drug Discov Devel 2009;12:458-467.
30. Kleiman RJ, Kimmel LH, Bove SE, et al. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease. J Pharmacol Exp Ther 2010;336:64-76.
31. Pfizer. 2013. Study evaluating the safety, tolerability and brain function of 2 doses of PF-0254920 In subjects with early Huntington's disease. New York: Pfizer.
32. Omeros. FDA grants fast track designation to Omeros' OMS824 Huntington's disease program. 2014. Seattle, WA: Omeros.
33. Omeros. Omeros begins dosing in second phase II study of OMS824 in Huntington's Disease. 2014. Seattle, WA: Omeros.
34. Pharmaceuticals Auspex. SD-809: a VMAT-2 inhibitor for the agram (phase 3 ongoing). http://www.auspexpharma.com/pipeline/. Accessed July 2014.
35. Aronin N and DiFiglia M. Huntingtin-Lowering Strategies in Huntington's Disease: Antisense Oligonucleotides, Small RNAs, and Gene Editing. Mov Disord 2014;29:1455-1461.
36. Miller TM, Pestronk A, David W, et al. An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 2013;12:435-442.
37. ISIS-ROCHE. Roche and Isis Pharmaceuticals form alliance for Huntington's Disease. 2013. http://www.roche.com/research_and_development/partnering/partnering-media/partnering_news-2013-04-08.htm, consulted June 2014.
38. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington Disease. Neurology 2006;66(3):366-372.
39. Huntington Study Group Cohort Investigators, Dorsey E. Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PloS One 2012;7:e29522.
40. Orth M, Handley OJ, Schwenke C, et al.; Investigators of the European Huntington's Disease Network. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. PLoS Curr 2010;2:RRN1184.
41. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009;3:CD006456.
42. Landwehrmeyer GB, Dubois B, de Yebenes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007;62:262-272.
43. Gewandter JS, Dworkin RH, Turk DC, et al. Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. Pain 2014 May 24. pii: S0304-3959(14)00258-9. doi:10.1016/j.pain.2014.05.025. [Epub ahead of print].
44. Chow SC, Corey R. Benefits, challenges and obstacles of adaptive clinical trial designs. Orphanet J Rare Dis 2010;6:79.
45. Rosas HD, Doros G, Gevorkian S, et al. PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 2014;82:850-857.
46. Banner Alzheimer Institute. Groundbreaking Alzheimer's disease prevention trial announced. 2012. http://banneralz.org/api-news-items/banner-alzheimers-partners-with-novartis.aspx, consulted June 2014.
47. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.
48. Shoulson I. Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology 1981;31:1333-1335.
49. The Huntington Study Group. Unified Huntington's disease rating scale: reliability and consistency. Mov Disord 1996;11:136-142.
50. Unified Huntington's Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136-142.
51. Siesling S, van Vugt JPP, Zwinderman KAH, Kieburtz K, Roos RAC. Unified Huntington's disease rating scale: a follow up. Mov Disord 1998;13:915-919.
52. Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW. Assessment of involuntary choreatic movements in Huntington's disease-toward objective and quantitative measures. Mov Disord 2011;26:2267-2273.
53. Reilmann R, Bohlen S, Klopstock T, et al. Tongue force analysis assesses motor phenotype in premanifest and symptomatic Huntington's disease. Mov Disord 2010;25:2195-2202.
54. Reilmann R, Bohlen S, Klopstock T, et al. Grasping premanifest Huntington's disease-shaping new endpoints for new trials. Mov Disord 2010;25:2858-2862.
55. Scahill RI, Hobbs NZ, Say MJ, et al. Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy. Hum Brain Mapp 2013;34:519-529.
56. Harrington DL, Smith MM, Zhang Y, Carlozzi NE, Paulsen JS; PREDICT-HD Investigators of the Huntington Study Group. Cognitive domains that predict time to diagnosis in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 2012;83:612-619.
57. Stout JC, Jones R, Labuschagne I, et al. Evaluation of longitudinal 12 and 24 month cognitive outcomes in premanifest and early Huntington's disease. J Neurol Neurosurg Psychiatry 2012;83:687-694.
58. Stout JC, Queller S, Baker KN, et al. HD-CAB: a cognitive assessment battery for clinical trials in Huntington's disease. Mov Disord 2014 Jul 7. doi: 10.1002/mds.25964.
59. Vaccarino AL, Anderson K, Borowsky B, et al. An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers. Mov Disord 2011;26:877-884.
60. Thompson JC, Harris J, Sollom AC, et al. Longitudinal evaluation of neuropsychiatric symptoms in Huntington's disease. J Neuropsychiatry Clin Neurosci 2011;24:53-60.